Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Prostate Cancer and Prostatic Diseases is Scopus-indexed (Q1, CiteScore 11.9), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Nature.
Checked against the index lists dated .
ISSN 1365-7852Verify ISSN ↗1476-5608Verify ISSN ↗
Publisher: Springer Nature
Cost to publish: About US$5,190 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Urology | 3 / 123 | 97th | Q1 |
| Oncology | 44 / 428 | 89th | Q1 |
| Cancer Research | 35 / 233 | 85th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1997–present, best quartile Q1, CiteScore 11.9.
Prostate Cancer and Prostatic Diseases is Q1 in Urology (rank 3 of 123), Q1 in Oncology (rank 44 of 428) and Q1 in Cancer Research (rank 35 of 233), by CiteScore 2025.
Prostate Cancer and Prostatic Diseases is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11.9, which places it in quartile Q1 at the 97th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.025, quartile Q1, with an H-index of 85.
The publisher lists an article processing charge of about US$5,190 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Prostate Cancer and Prostatic Diseases is published by Springer Nature. Its print ISSN is 1365-7852 and its online ISSN is 1476-5608.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Prostate Cancer and Prostatic Diseases has an h-index of 100 and a 2-year mean of 5.65 citations per paper (OpenAlex). Its Scopus CiteScore is 11.9, quartile Q1. On 2-year citations it ranks #2 of 123 Scopus journals in Urology.
Prostate Cancer and Prostatic Diseases published 137 papers in 2025; its busiest recent year was 2021 with 166. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from United States (32.5%), China (18.5%) and Italy (13%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (1.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.